UCBJF:OTCMKTS
UCB SA
$269.66
arrow_upward
+3.88%(+10.07) 1D
Jul 31, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJF...
Open
$260.32
High
$269.66
Low
$260.32
Mkt. cap
43.59B
Avg. vol.
651.00
Volume
49.00
52-wk high
$345.39
52-wk low
$207.00
Beta
0.59
Shares outstanding
194.51M
No. of employees
10K
Open
$260.32
High
$269.66
Low
$260.32
Mkt. cap
43.59B
Avg. vol.
651.00
Volume
49.00
52-wk high
$345.39
52-wk low
$207.00
Beta
0.59
Shares outstanding
194.51M
No. of employees
10K
News stories
From sources across the web
Investing.com
·
3 days ago
Earnings call transcript: UCB lifts 2026 outlook as BIMZELX sales double in H1 2026
Investing.com South Africa
·
3 days ago
UCB H1 2026 slides: BIMZELX doubles sales, guidance upgraded By Investing.com
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9.76K
FoundedJan 18, 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com
AI content may include mistakes. Learn more